NanOlogy
  • Home
  • About
  • Technology
    • Overview
    • Purcision Technology
  • Development
    • Investigational Drugs
    • Pipeline
    • Clinical Trials
    • Partnering Opportunities
  • News & Publications
  • Contact Us
    • Partnering Opportunities
    • Physicians and Patients
Post placeholder image
February 5, 2018 in NanOlogy in the News

Houston Business Journal: NanOlogy to Update Clinical Program at BIO CEO Conference

NanOlogy 0 Like Post Comments Off on Houston Business Journal: NanOlogy to Update Clinical Program at BIO CEO Conference
Read More
Post placeholder image
February 5, 2018 in NanOlogy Press Release, Soria

NanOlogy to Update Clinical Program Transforming Treatment of Cancer at BIO CEO and Investor Conference

NanOlogy 0 Like Post Comments Off on NanOlogy to Update Clinical Program Transforming Treatment of Cancer at BIO CEO and Investor Conference

  Download PDF NanOlogy to Update Clinical Program Transforming Treatment of Cancer at BIO CEO and Investor Conference   Company has six Phase 2 trials underway for cancer an ...

Read More
NanOlogy

NanOlogy investigational drugs have not yet been proven to be safe and effective in accordance with the requirements of the U.S. FDA and are not approved by FDA or any other jurisdiction for commercial distribution. NanOlogy, NanoPac, and NanoDoce are trademarks of NanOlogy, LLC.    Purcision is a trademark to CritiTech, Inc.  © NanOlogy LLC      Legal